

05-23-03

CASE 4-32185P1

1624#6  
6/4/03  
89



FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV 335541225 US  
Express Mail Label Number

May 22, 2003  
Date of Deposit

RECEIVED

MAY 27 2003

TECH CENTER 1600/2300

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1624

PAIVI JAANA KUKKOLA

Examiner: T. Truong

APPLICATION NO: 09/966,960 ✓

FILED: SEPTEMBER 28, 2001 ✓

FOR: THYROMIMETIC ORGANIC COMPOUNDS ✓

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with 37 C.F.R. §1.56, applicant wishes to call the Examiner's attention to the reference cited on the attached form PTO-1449, namely U.S. patent 6,545,018 issued April 8, 2003.

Copy of this reference is enclosed herewith.

Certification: That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in §1.56(c) more than three months prior to the filing of the information disclosure statement.

The item of information referred to herein is U.S. patent 6,545,018 issued April 8, 2003.


The Examiner is requested to reconsider the foregoing information in relation to this application and indicate that the reference was considered by returning a copy of the initialed PTO-1449 form.

Respectfully submitted,

Novartis  
Corporate Intellectual Property  
One Health Plaza, Building 430  
East Hanover, NJ 07936-1080

NG/pk

Encl.: PTO-1449 form

  
\_\_\_\_\_  
Norbert Gruenfeld  
Agent for Applicant  
Reg. No. 30,061  
(862) 778-7853